DelveInsight’s “Cholangiocarcinoma Market Insights, Epidemiology, and Market Forecast–2034” report offers an in-depth understanding of Cholangiocarcinoma, historical and forecasted epidemiology as well as the Cholangiocarcinoma market trends in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
Get a Free sample for the Cholangiocarcinoma Market Forecast, Size & Share Analysis Report
Some of the Key Facts of the Cholangiocarcinoma Market Report:
- The United States accounted for the largest Cholangiocarcinoma market size, in comparison to EU4 (Germany, France, Italy, and Spain), the UK, and Japan in 2023.
- In February 2024, Biosyngen announced that BST02 had been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of all types of liver cancer, including hepatocellular carcinoma and cholangiocarcinoma.
- In November 2021, TransThera announced that the US FDA had granted Fast Track Designation to its Phase II stage product TT-00420 (tinengotinib) for the treatment of patients with cholangiocarcinoma who have no standard treatment options.
- The overall cholangiocarcinoma incidence across the 7MM was around 45,000 in 2023, out of which ~45% cases were intrahepatic.
- Cholangiocarcinoma represents approximately 3% of gastrointestinal malignancies worldwide and constitutes around 10–15% of all primary liver cancers, being only second to hepatocellular carcinoma.
- As per DelveInsight’s estimates, the total incident cases of cholangiocarcinoma in the United States were ~14,000 in 2023.
- In the United States, out of all the cholangiocarcinoma cases, intrahepatic cancer accounted for around 6,000 cases.
- Cholangiocarcinoma is primarily diagnosed in the elderly and is more prevalent in the population aged 80 and above.
- The mutation-specific cases of cholangiocarcinoma were highest in TP53 mutations, followed by KRAS mutations in the 7MM.
- Currently, an estimated 80% of the Cholangiocarcinoma patient pool receive treatment in adjuvant settings.
- Japan accounts for the second highest Cholangiocarcinoma market size in the 7MM during the forecast period 2024–2034.
- Among EU4 and the UK, Italy had the highest Cholangiocarcinoma market size.
Key Cholangiocarcinoma Companies:
Incyte, Agios Pharmaceuticals/Servier Pharmaceuticals, Taiho, TransThera Sciences, Senhwa Biosciences, Lisata Therapeutics, Relay Therapeutics, Genoscience Pharma, Virogin Biotech, and others.
Key Cholangiocarcinoma Therapies:
PEMAZYRE (pemigatinib), TIBSOVO (ivosidenib), LYTGOBI (futibatinib), Tinengotinib (TT-00420), Silmitasertib (CX-4945), LSTA1, RLY-4008, GNS561 + trametinib, VG161, and others.
The Cholangiocarcinoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cholangiocarcinoma pipeline products will significantly revolutionize the Cholangiocarcinoma market dynamics.
Cholangiocarcinoma Overview
Cholangiocarcinoma (CCA) is an umbrella term that denotes cancer arising from the biliary tree. Multiple subtypes exist depending on their anatomical origin: intrahepatic Cholangiocarcinoma (iCCA), perihilar Cholangiocarcinoma (pCCA), and distal extrahepatic Cholangiocarcinoma (dCCA). Perihilar CCA and distal CCA collectively are called extrahepatic cholangiocarcinoma (eCCA). One of the frequent symptoms of cholangiocarcinoma is jaundice, caused when bile ducts become blocked, preventing the normal flow of bile from the liver to the intestines. While surgical resection remains the only potentially curative option for early-stage disease, most patients are diagnosed at an advanced stage, limiting treatment options to systemic chemotherapy and targeted therapies.
To Know in detail about the Cholangiocarcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cholangiocarcinoma Market Forecast
Cholangiocarcinoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Cholangiocarcinoma Epidemiology Segmentation:
The Cholangiocarcinoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
- Incident Cases of Cholangiocarcinoma
- Incident Cases of Cholangiocarcinoma by Tumor Location
- Mutation-specific Cases of Cholangiocarcinoma
- Age-specific Cases of Cholangiocarcinoma
- Stage-specific Cases of Cholangiocarcinoma
- Total Treated Cases of Cholangiocarcinoma
Download the report to understand which factors are driving Cholangiocarcinoma epidemiology trends @ Cholangiocarcinoma Market Forecast
Cholangiocarcinoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cholangiocarcinoma market or expected to get launched during the study period. The analysis covers Cholangiocarcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Cholangiocarcinoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Discover more about therapies set to grab major Cholangiocarcinoma market share @ Cholangiocarcinoma Treatment Landscape
Cholangiocarcinoma Market Drivers
- Rising global incidence of cholangiocarcinoma and increasing awareness are driving demand for effective treatment options.
- Advances in next-generation sequencing enabling identification of targetable mutations (FGFR2, IDH1/2, KRAS) are fueling the development of precision oncology therapies.
- Growing unmet need for curative and second-line therapies is encouraging significant R&D investments by pharma companies.
- Regulatory support through Breakthrough Designations, Orphan Drug Designations, and Fast Track Designations is accelerating therapeutic development.
Cholangiocarcinoma Market Barriers
- Late-stage diagnosis due to lack of early symptoms and limited screening programs severely restricts treatment options and outcomes.
- High heterogeneity of the disease and diverse molecular subtypes complicate the development of broadly effective therapies.
- Limited patient populations for rare mutations (FGFR2 fusions, IDH1 mutations) restrict market size for targeted therapies.
- High cost of approved targeted therapies and variable reimbursement across geographies pose accessibility challenges.
Scope of the Cholangiocarcinoma Market Report
- Study Period: 2020–2034
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Companies: Incyte, Agios Pharmaceuticals/Servier Pharmaceuticals, Taiho, TransThera Sciences, Senhwa Biosciences, Lisata Therapeutics, Relay Therapeutics, Genoscience Pharma, Virogin Biotech, and others
- Key Therapies: PEMAZYRE (pemigatinib), TIBSOVO (ivosidenib), LYTGOBI (futibatinib), Tinengotinib, Silmitasertib (CX-4945), LSTA1, RLY-4008, GNS561 + trametinib, VG161, and others
- Therapeutic Assessment: Cholangiocarcinoma current marketed and emerging therapies
- Market Dynamics: Cholangiocarcinoma market drivers and Cholangiocarcinoma market barriers
- Competitive Intelligence: SWOT analysis, PESTLE analysis, Porter’s Five Forces, BCG Matrix, and market entry strategies
To know more about Cholangiocarcinoma companies working in the treatment market, visit @ Cholangiocarcinoma Clinical Trials and Therapeutic Assessment
Table of Contents
1. Cholangiocarcinoma Market Report Introduction
2. Executive Summary for Cholangiocarcinoma
3. SWOT Analysis of Cholangiocarcinoma
4. Cholangiocarcinoma Patient Share (%) Overview at a Glance
5. Cholangiocarcinoma Market Overview at a Glance
6. Cholangiocarcinoma Disease Background and Overview
7. Cholangiocarcinoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Cholangiocarcinoma
9. Cholangiocarcinoma Current Treatment and Medical Practices
10. Cholangiocarcinoma Unmet Needs
11. Cholangiocarcinoma Emerging Therapies
12. Cholangiocarcinoma Market Outlook
13. Country-Wise Cholangiocarcinoma Market Analysis (2020–2034)
14. Cholangiocarcinoma Market Access and Reimbursement of Therapies
15. Cholangiocarcinoma Market Drivers
16. Cholangiocarcinoma Market Barriers
17. Cholangiocarcinoma Appendix
18. Cholangiocarcinoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Mehul Malhotra
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432, Las Vegas, NV, United States
Website: https://www.delveinsight.com/
